• Publications
  • Influence
Percutaneous tricuspid valve therapies: the new frontier
Moderate-to-severe tricuspid regurgitation (TR) affects ∼1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreatedExpand
  • 92
  • 6
Conventional surgery and transcatheter closure via surgical transapical approach for paravalvular leak repair in high-risk patients: results from a single-centre experience.
OBJECTIVES Paravalvular leaks (PVL) occur in up to 17% of all surgically implanted prosthetic valves. Re-operation is associated with high morbidity and mortality. Transcatheter closure via aExpand
  • 54
  • 3
Surgical treatment of paravalvular leak: Long-term results in a single-center experience (up to 14 years).
OBJECTIVES The aim of this study is to report the long-term outcomes (median follow-up time, 7 years; range, 1 month to 14 years) of patients who underwent surgery for paravalvular leak in ourExpand
  • 60
  • 2
  • PDF
Thoracoscopic appendage exclusion with an atriclip device as a solo treatment for focal atrial tachycardia.
A 15-year-old boy with incessant drug-refractory atrial tachycardia was referred to our department for an ablation procedure. The tachycardia was diagnosed at 13 years of age during routine medicalExpand
  • 45
  • 2
  • PDF
Severe thrombocytopenia and its clinical impact after implant of the stentless Freedom Solo bioprosthesis.
BACKGROUND This single-center study analyzed the occurrence of severe thrombocytopenia and its clinical effect after concomitant and isolated aortic valve replacement (AVR) with the stentless FreedomExpand
  • 20
  • 2
A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The EndoSCORE.
BACKGROUND The aim of this large retrospective study was to provide a logistic risk model along an additive score to predict early mortality after surgical treatment of patients with heart valve orExpand
  • 23
  • 2
Mitral valve repair
Mitral regurgitation (MR) is the most common valvular heart disease in the Western world. The MR can be either organic (mainly degenerative in Western countries) or functional (secondary to leftExpand
  • 18
  • 2
  • PDF
Current challenges in interventional mitral valve treatment.
Transcatheter mitral valve therapies have emerged as an alternative option in high surgical risk or inoperable patients with severe and symptomatic mitral regurgitation (MR). As multiple technologiesExpand
  • 7
  • 2
  • PDF
Transcatheter mitral valve chord repair.
The field of mitral valve disease diagnosis and management is rapidly evolving. New understanding of pathophysiology and improvements in the adoption of sophisticated multimodality imaging modalitiesExpand
  • 8
  • 2
  • PDF
First-in-Man Implantation of a Tricuspid Annular Remodeling Device for Functional Tricuspid Regurgitation.
Tricuspid regurgitation (TR) is a common finding in patients with left-sided disease, and is associated with poor outcome and predicts poor survival, heart failure, and reduced functional capacityExpand
  • 87
  • 1
  • PDF